http://purl.org/np/RA-SgNkbxN... RA-SgNkbxN

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

https://dailymed.nlm.nih.gov/d...79-d0a4-4af7-b09b-96ee5a5b2a37 drugInfo.cfm?setid=2e325d79-d0a4-4af7-b09b-96ee5a5b2a37

Sarah Chenine

2021-04-05T13:18:27.533Z

http://purl.org/np/RA-SgNkbxN... RA-SgNkbxN

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/ns/prov#value value

If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate oral suspension can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children

Sarah Chenine

2021-04-05T13:18:27.533Z

http://purl.org/np/RA-SgNkbxN... RA-SgNkbxN

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://purl.org/np/RA-SgNkbxN...#medtherapy medtherapy

http://www.w3.org/ns/prov#wasDerivedFrom wasDerivedFrom

Sarah Chenine

2021-04-05T13:18:27.533Z